ROCKWELL MEDICAL, INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ROCKWELL MEDICAL, INC. (Registrant) | |
| By: | /s/ Mark Strobeck |
| Mark Strobeck, Ph.D. | |
| President and Chief Executive Officer | |
| Date: | March 20, 2025 |
POWER OF ATTORNEY
KNOW BY ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Mark Strobeck and Megan Timmins, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file, any and all documents in connection therewith, with the Securities and Exchange commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their and his or her substitute or substitutes, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of registrant and in the capacities and on the dates indicated.
| SIGNATURE | TITLE | DATE |
|---|---|---|
| /s/ Mark Strobeck | President, Chief Executive Officer and Director (Principal Executive Officer) | March 20, 2025 |
| Mark Strobeck, Ph.D. | ||
| /s/ Jesse Neri | Senior Vice President, Chief Financial Officer (Principal Financial Officer) | March 20, 2025 |
| Jesse Neri | ||
| /s/ Nicholas Fanslau | Controller (Principal Accounting Officer) | March 20, 2025 |
| Nicholas Fanslau | ||
| /s/ Robert S. Radie | Director and Chairman of the Board | March 20, 2025 |
| Robert S. Radie | ||
| /s/ John G. Cooper | Director | March 20, 2025 |
| John G. Cooper | ||
| /s/ Joan Lau | Director | March 20, 2025 |
| Joan Lau, Ph.D. | ||
| /s/ Allen R. Nissenson | Director | March 20, 2025 |
| Allen R. Nissenson, M.D. | ||
| /s/ Mark H. Ravich | Director | March 20, 2025 |
| Mark H. Ravich | ||
| /s/ Andrea Heslin Smiley | Director | March 20, 2025 |
| Andrea Heslin Smiley | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| PAGE | |
| Report of Independent Registered Public Accounting Firm - EisnerAmper LLP (PCAOB Identification Number 274) | F-2 |
|---|---|
| Consolidated Balance Sheets at December 31, 2024 and 2023 | F-4 |
| Consolidated Statements of Operations for the years ended December 31, 2024 and 2023 | F-5 |
| Consolidated Statements of Comprehensive Loss for the years ended December 31, 2024 and 2023 | F-6 |
| Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2024 and 2023 | F-7 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023 | F-8 |
| Notes to the Consolidated Financial Statements | F-9 – F-33 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.